JAMA today published the results of three randomized controlled trials spanning 12 countries, a prospective meta-analysis, and a commentary, all but one—which had inconclusive results—supporting the use of systemic corticosteroids in critically ill COVID-19 patients, regardless of age, sex, duration of symptoms before treatment, or the need for mechanical ventilation.Safe, inexpensive, and widely available, corticosteroids like dexamethasone, hydrocortisone, and methylprednisolone are believed to treat COVID-19 by reducing lung inflammation in patients who require supplemental oxygen.Lower 28-day death ratesThe meta-analysis of the three corticosteroid trials published today, plus four other such trials, showed that 28-day rates of death